Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Gastroenterology ; 137(1): 285-96, 296.e1-11, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19362089

RESUMO

BACKGROUND & AIMS: The molecular mechanisms of lymphoproliferation associated with the disruption of interferon (IFN) signaling and chronic hepatitis C virus (HCV) infection are poorly understood. Lymphomas are extrahepatic manifestations of HCV infection; we sought to clarify the molecular mechanisms of these processes. METHODS: We established interferon regulatory factor-1-null (irf-1(-/-)) mice with inducible and persistent expression of HCV structural proteins (irf-1/CN2 mice). All the mice (n = 900) were observed for at least 600 days after Cre/loxP switching. Histologic analyses, as well as analyses of lymphoproliferation, sensitivity to Fas-induced apoptosis, colony formation, and cytokine production, were performed. Proteins associated with these processes were also assessed. RESULTS: Irf-1/CN2 mice had extremely high incidences of lymphomas and lymphoproliferative disorders and displayed increased mortality. Disruption of irf-1 reduced the sensitivity to Fas-induced apoptosis and decreased the levels of caspases-3/7 and caspase-9 messenger RNA species and enzymatic activities. Furthermore, the irf-1/CN2 mice showed decreased activation of caspases-3/7 and caspase-9 and increased levels of interleukin (IL)-2, IL-10, and Bcl-2, as well as increased Bcl-2 expression, which promoted oncogenic transformation of lymphocytes. IL-2 and IL-10 were induced by the HCV core protein in splenocytes. CONCLUSIONS: Disruption of IFN signaling resulted in development of lymphoma, indicating that differential signaling occurs in lymphocytes compared with liver. This mouse model, in which HCV expression and disruption of IFN signaling synergize to promote lymphoproliferation, will be an important tool for the development of therapeutic agents that target the lymphoproliferative pathway.


Assuntos
Hepacivirus/metabolismo , Hepatite C Crônica/complicações , Interleucinas/metabolismo , Transtornos Linfoproliferativos/imunologia , Transtornos Linfoproliferativos/virologia , Transdução de Sinais , Proteínas Virais/metabolismo , Receptor fas/metabolismo , Fatores Etários , Animais , Apoptose , Linfócitos B/imunologia , Linfócitos B/virologia , Caspases/metabolismo , Proliferação de Células , Modelos Animais de Doenças , Feminino , Hepacivirus/genética , Hepatite C Crônica/imunologia , Hepatite C Crônica/patologia , Fator Regulador 1 de Interferon/deficiência , Fator Regulador 1 de Interferon/genética , Fator Regulador 1 de Interferon/metabolismo , Interleucina-10/metabolismo , Interleucina-12/metabolismo , Interleucina-2/metabolismo , Linfoma/imunologia , Linfoma/virologia , Transtornos Linfoproliferativos/patologia , Masculino , Camundongos , Camundongos Knockout , Camundongos Transgênicos , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Baço/imunologia , Baço/virologia , Linfócitos T/imunologia , Linfócitos T/virologia , Fatores de Tempo , Proteínas do Core Viral/metabolismo , Proteínas do Envelope Viral/metabolismo , Proteínas não Estruturais Virais/metabolismo , Proteínas Virais/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...